SCHEMBL30274243

SCHEMBL30274243

COc1ccc2c(c1)SCC1=C2c2cc(OC)c(OC)cc2C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
HTT P42858 1/20 0.42
CA12 O43570 6/20 0.41
CA9 Q16790 6/20 0.41
CA1 P00915 5/20 0.41
CA2 P00918 5/20 0.41
EGFR P00533 1/20 0.40
KDR P35968 2/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
METAP1 P53582 1/20 0.38
LMNA P02545 2/20 0.37
CA7 P43166 2/20 0.37
CA14 Q9ULX7 2/20 0.37
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA13 Q8N1Q1 1/20 0.36
CA5B Q9Y2D0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25034013 1.00 KDM4E (0.42) KDM4EHTTCA12CA9CA1
SCHEMBL8938825 0.77 ALDH1A1 (0.44) KDM4EMETAP1LMNAALDH1A1CYP3A4
SCHEMBL8938855 0.72 ALDH1A1 (0.47) KDM4EHTTCA12CA9CA1
SCHEMBL29853726 0.70 CA12 (0.53) KDM4EHTTCA12CA9CA1
SCHEMBL26768607 0.70 CA12 (0.53) KDM4EHTTCA12CA9CA1
SCHEMBL68574 0.67 KDM4E (0.71) KDM4EHTTCA12CA9CA1
SCHEMBL8938848 0.66 LMNA (0.50) KDM4EHTTCA12CA9CA1
SCHEMBL31123564 0.64 ALDH1A1 (0.42) KDM4EHTTCA12CA9CA1
SCHEMBL30777630 0.64 METAP1 (0.63) CA1CA2MAOBMETAP1CA4
SCHEMBL4581239 0.64 METAP1 (0.63) CA1CA2MAOBMETAP1CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129076-A1 FUSED TETRACYCLIC COMPOUNDS, COMPOSITIONS AND DIAGNOSTIC APPLICATIONS THEREOF BENAZIR FATHIMA (IN) 2025-04-24 US claimed
WO-2023017548-A1 FUSED TETRACYCLIC COMPOUNDS, COMPOSITIONS AND DIAGNOSTIC APPLICATIONS THEREOF BENAZIR J DR FATHIMA (IN) 2023-02-16 WO claimed
US-20250129076-A1 FUSED TETRACYCLIC COMPOUNDS, COMPOSITIONS AND DIAGNOSTIC APPLICATIONS THEREOF BENAZIR FATHIMA (IN) 2025-04-24 US disclosed
WO-2023017548-A1 FUSED TETRACYCLIC COMPOUNDS, COMPOSITIONS AND DIAGNOSTIC APPLICATIONS THEREOF BENAZIR J DR FATHIMA (IN) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129076-A1 FUSED TETRACYCLIC COMPOUNDS, COMPOSITIONS AND DIAGNOSTIC APPLICATIONS THEREOF POLRMT, POLM, DNTT KDM4E 4802/4885HTT 644/4885CA12 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.